BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JS207 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JS207\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885385-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:JS207: Phase 2 readout est. (NCT06885385)
DESCRIPTION:JS207\, phase 2.\nStudy: A Phase 2 Study Evaluating the Safety 
 and Efficacy of JS207 With or Without JS015 in Combination With Chemothera
 py in Patients With Colorectal Cancer\nEstimated primary completion: 27 No
 vember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068853
 85
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571422-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:JS207: Phase 1 readout est. (NCT06571422)
DESCRIPTION:JS207\, phase 1.\nStudy: Phase I Study of WJ47156 Monotherarpy 
 and in Combination With Other Therapy in Advanced Solid Tumors\nEstimated 
 primary completion: 15 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06571422
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944470-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:JS207: Phase 2 readout est. (NCT06944470)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207 Com
 bined With Chemotherapy in Subjects With Stage II-III NSCLC\nEstimated pri
 mary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/js207#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06944470
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309276-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JS207: Phase 2 readout est. (NCT07309276)
DESCRIPTION:JS207\, phase 2.\nStudy: A Phase II Clinical Study Evaluating t
 he Combination Therapy of JS212 in Patients With Advanced Lung Cancer\nEst
 imated primary completion: 30 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07309276
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480733-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JS207: Phase 2 readout est. (NCT07480733)
DESCRIPTION:JS207\, phase 2.\nStudy: Phase II Study of JS212/JS213 as Monot
 herapy and in Combination in Patients With Advanced Malignant Solid Tumors
 \nEstimated primary completion: 30 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/js207#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07480733
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:JS207: Phase 2 readout est. (NCT07503756)
DESCRIPTION:JS207\, phase 2.\nStudy: JS212 Combination Therapies in Metasta
 tic Colorectal Cancer\nEstimated primary completion: 30 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07503756
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466160-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 1/2 readout est. (NCT07466160)
DESCRIPTION:JS207\, phase 1/2.\nStudy: A Phase Ib/II Study of 7MW3711 Combi
 ned With JS207 in Advanced Solid Tumors\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746
 6160
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954467-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06954467)
DESCRIPTION:JS207\, phase 2\, Hepatocellular Carcinoma.\nStudy: JS207 Combi
 ned With JS007 as First-line Treatment for Advanced Hepatocellular Carcino
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/js207#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06954467
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT05582499)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: Fudan University Shang
 hai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuva
 nt Therapy\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690787-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT07690787)
DESCRIPTION:JS207\, phase 2.\nStudy: JS207 a Bispecific Antibody Against PD
 1-VEGF in Nasopharyngeal Carcinoma\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07690787
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969027-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06969027)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207Comb
 ined With Chemotherapy in First-line Treatment of Advanced NSCLC\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06969027
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT07876557)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: A Clinical Study to Ev
 aluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy
  in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07876557
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045311-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20280322
DTEND;VALUE=DATE:20280323
SUMMARY:JS207: Phase 2 readout est. (NCT07045311)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: JS207 Combination Ther
 apy in Triple-negative Breast Cancer\nEstimated primary completion: 22 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045311
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953323-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:JS207: Phase 1/2 readout est. (NCT06953323)
DESCRIPTION:JS207\, phase 1/2.\nStudy: A Phase I/II Study of WJB001 Combina
 tion Therapy on Safety and Efficacy for Advanced Solid Tumors\nEstimated p
 rimary completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/js207#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06953323
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823348-2239@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:JS207: Phase 3 readout est. (NCT07823348)
DESCRIPTION:JS207\, phase 3\, Hepatocellular Carcinoma.\nStudy: JS207 Plus 
 JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Adva
 nced Liver Cancer\nEstimated primary completion: 30 October 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07823348
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
